Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Can Pfizer Leap Over the Competition With This Potential Blockbuster?

Source: 
Motley Fool
snippet: 

The company's newly approved treatment, Vyndamax, also known as tafamidis, is priced like a rare disease drug, at around $225,000 per year. There are enough people out there suffering from the conditions it's approved for to easily drive 10-figure annual sales, but it's far from guaranteed that Pfizer will be able to take a leading share in this increasingly crowded market.